Sanofi’s Tzield approved in the US as the first disease-modifying therapy for patients recently diagnosed with stage 3 type 1 diabetes Accelerat...
TALVEY® plus daratumumab with or without pomalidomide showed progression-free survival of up to 81.3% and overall survival of up to ...
Hartwig to adopt Ultima Genomics' UG200 sequencing system to accelerate implementation of whole-genome-based clinical genomics workflows on Solaris 2.0 t...
Used as a predictive biomarker, the first-of-its-kind VENTANA MMR RxDx Panel helps identify cancer patients eligible for treatment ...
The expanded partnership adds Denmark, Finland, Norway and Sweden to GENESIS Pharma’s existing network of thirteen Southeast European markets. ...
Clinical Trial approval for TCX-001 is another significant development milestone for T-CURX and marks the transition of T-CURX from a pre-clinical to a...
Senior secured term loan of up to CHF 250 million with a 5‑year maturity at a fixed 7% interest rate First tranche will fully refinance the existing...
As pharmaceutical manufacturers face increasing pressure to maintain production continuity, ensure regulatory compliance, and manage ageing equipment, the ...
Approval Based Upon Phase 3 DeLLphi-304 Trial Demonstrating 40% Reduction in Risk of Death with IMDYLLTRA Compared to Chemotherapy Novel Treatment...
Service will be available to clinicians and healthcare providers to support patient assessments and diagnosis Scottish Brain Sciences (SBS) has ...
T-CURX leverages Pantherna’s deep expertise and proprietary technologies in LNP-based delivery of mRNA and DNA vectors to advance T-CURX innovati...
Compared with patients receiving hormone therapy alone, patients were nine times more likely to havelittle to no cancer remaining in the prostate after s...
UCB and Biogen Inc.announced that The Lancet, a world-leading medical journal, has published the full results from the Phase 3 PHOENYCS G...
Primrose Bio will supply its industry-leading carrier protein, PeliCRM197®, for vaccine development Intravacc has knowhow in vaccine conjugation a...
© 2026 Biopharma Boardroom. All Rights Reserved.
